Goldman Sachs Starts CVR Refining (CVRR) at Neutral
Get Alerts CVRR Hot Sheet
Price: $10.49 --0%
Rating Summary:
2 Buy, 5 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
2 Buy, 5 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Goldman Sachs initiates coverage on CVR Refining (NYSE: CVRR) with a Neutral. PT $37.00.
Analyst Arjun N. Murti comments, "CVR Refining is a variable-distribution refining MLP similar in structure to Alon USA Partners and Northern Tier Energy. The company is a pure-play on Cushing-area refining given its Coffeyville, Kansas and Wynnewood, Oklahoma plants, and, as a result, is highly leveraged to our bullish MidCon refining call. Relative to Buy-rated C-Corp refiners and refining MLPs, CVRR shows less upside, however, which it why we initiate with a Neutral rating."
For an analyst ratings summary and ratings history on CVR Refining click here. For more ratings news on CVR Refining click here.
Shares of CVR Refining closed at $30.48 yesterday.
Analyst Arjun N. Murti comments, "CVR Refining is a variable-distribution refining MLP similar in structure to Alon USA Partners and Northern Tier Energy. The company is a pure-play on Cushing-area refining given its Coffeyville, Kansas and Wynnewood, Oklahoma plants, and, as a result, is highly leveraged to our bullish MidCon refining call. Relative to Buy-rated C-Corp refiners and refining MLPs, CVRR shows less upside, however, which it why we initiate with a Neutral rating."
For an analyst ratings summary and ratings history on CVR Refining click here. For more ratings news on CVR Refining click here.
Shares of CVR Refining closed at $30.48 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DA Davidson Starts Everus (ECG) at Buy
- TD Cowen Assumes Atara Biotherapeutics (ATRA) at Buy
- TD Cowen Assumes Iovanace Biotherapeutics (IOVA) at Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share